Ritlecitinib approved for severe alopecia, impacting 400,000 UK individuals

theguardian.com

Ritlecitinib, a Pfizer tablet for severe alopecia, is recommended for NHS use, impacting 400,000 UK individuals. Nice's approval follows a September 2023 rejection, now backed by additional data and a price discount. Alopecia UK's CEO hails it as a monumental day, addressing the lack of NHS treatment options. An NHS spokesperson acknowledges the potential to benefit thousands. Patients still face barriers, urging NHS to keep referral pathways open.


With a significance score of 6.5, this news ranks in the top 0.1% of today's 28806 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: